{"entity":{"type":"insider","cik":"0001842875","url":"/insider/0001842875","json_url":"/insider/0001842875.json","name":"Innoviva Strategic Opportunities LLC","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":9,"n_filings":8,"first":"2021-01-28","last":"2022-07-13","span_basis":"filed_date"},"name_variants":[{"name":"Innoviva Strategic Opportunities LLC","source":"filing","n_filings":8,"first_seen":"2021-01-28","last_seen":"2022-07-13"}],"transactions":[{"id":6621133,"accession":"0001140361-22-025957","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001140361-22-025957","line_url":"/filing/0001140361-22-025957#line-2","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":null,"owner_name":"Innoviva Strategic Opportunities LLC; Innoviva, Inc.","owner_display_name":"Innoviva Strategic Opportunities LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":7598814.0,"shares_display":"7,598,814","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":16717390.8,"total_display":"16,717,390.80","total_whole":"16,717,391","shares_owned_after":29270476.0,"shares_owned_after_display":"29,270,476","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-11","filed_date":"2022-07-13","scope":"insider"},{"id":6621130,"accession":"0001140361-22-025957","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001140361-22-025957","line_url":"/filing/0001140361-22-025957#line-1","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":null,"owner_name":"Innoviva Strategic Opportunities LLC; Innoviva, Inc.","owner_display_name":"Innoviva Strategic Opportunities LLC","owner_url":null,"role":"Ten percent owner, Other","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":11671662.0,"shares_display":"11,671,662","price_per_share":2.2,"price_display":"2.20","price_state":"stated","total_value":25677656.4,"total_display":"25,677,656.40","total_whole":"25,677,656","shares_owned_after":21671662.0,"shares_owned_after_display":"21,671,662","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-07-08","filed_date":"2022-07-13","scope":"insider"},{"id":6280611,"accession":"0001567619-22-007861","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-007861","line_url":"/filing/0001567619-22-007861#line-1","is_derivative":false,"issuer_cik":"0000921114","issuer_name":"Armata Pharmaceuticals, Inc.","issuer_ticker":"ARMP","issuer_name_source":null,"issuer_url":"/issuer/0000921114","owner_cik":null,"owner_name":"Innoviva Strategic Opportunities LLC; Innoviva, Inc.","owner_display_name":"Innoviva Strategic Opportunities LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5385208.0,"shares_display":"5,385,208","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":26926040.0,"total_display":"26,926,040.00","total_whole":"26,926,040","shares_owned_after":16365969.0,"shares_owned_after_display":"16,365,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-03-31","filed_date":"2022-04-01","scope":"insider"},{"id":6226522,"accession":"0001567619-22-003750","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-22-003750","line_url":"/filing/0001567619-22-003750#line-1","is_derivative":false,"issuer_cik":"0000921114","issuer_name":"Armata Pharmaceuticals, Inc.","issuer_ticker":"ARMP","issuer_name_source":null,"issuer_url":"/issuer/0000921114","owner_cik":null,"owner_name":"Innoviva, Inc.; Innoviva Strategic Opportunities LLC","owner_display_name":"Innoviva, Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3614792.0,"shares_display":"3,614,792","price_per_share":5.0,"price_display":"5.00","price_state":"stated","total_value":18073960.0,"total_display":"18,073,960.00","total_whole":"18,073,960","shares_owned_after":10980761.0,"shares_owned_after_display":"10,980,761","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-02-09","filed_date":"2022-02-11","scope":"insider"},{"id":4563213,"accession":"0001567619-21-019063","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-019063","line_url":"/filing/0001567619-21-019063#line-1","is_derivative":false,"issuer_cik":"0000921114","issuer_name":"Armata Pharmaceuticals, Inc.","issuer_ticker":"ARMP","issuer_name_source":null,"issuer_url":"/issuer/0000921114","owner_cik":null,"owner_name":"Innoviva Strategic Opportunities LLC; Innoviva, Inc.","owner_display_name":"Innoviva Strategic Opportunities LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1212122.0,"shares_display":"1,212,122","price_per_share":3.3,"price_display":"3.30","price_state":"stated","total_value":4000002.6,"total_display":"4,000,002.60","total_whole":"4,000,003","shares_owned_after":7365969.0,"shares_owned_after_display":"7,365,969","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-10-29","filed_date":"2021-11-01","scope":"insider"},{"id":4389851,"accession":"0001567619-21-012030","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-012030","line_url":"/filing/0001567619-21-012030#line-1","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":null,"owner_name":"Innoviva Strategic Opportunities LLC; Innoviva, Inc.","owner_display_name":"Innoviva Strategic Opportunities LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6268975.0,"shares_display":"6,268,975","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":12537950.0,"total_display":"12,537,950.00","total_whole":"12,537,950","shares_owned_after":10000000.0,"shares_owned_after_display":"10,000,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-06-11","filed_date":"2021-06-11","scope":"insider"},{"id":4643687,"accession":"0001567619-21-010772","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-010772","line_url":"/filing/0001567619-21-010772#line-1","is_derivative":false,"issuer_cik":"0001080014","issuer_name":"Entasis Therapeutics Holdings Inc.","issuer_ticker":"ETTX","issuer_name_source":null,"issuer_url":"/issuer/0001080014","owner_cik":null,"owner_name":"Innoviva Strategic Opportunities LLC; Innoviva, Inc.","owner_display_name":"Innoviva Strategic Opportunities LLC","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3731025.0,"shares_display":"3,731,025","price_per_share":2.0,"price_display":"2.00","price_state":"stated","total_value":7462050.0,"total_display":"7,462,050.00","total_whole":"7,462,050","shares_owned_after":3731025.0,"shares_owned_after_display":"3,731,025","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-03","filed_date":"2021-05-20","scope":"insider"},{"id":4147103,"accession":"0001567619-21-006518","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001567619-21-006518","line_url":"/filing/0001567619-21-006518#line-1","is_derivative":false,"issuer_cik":"0000921114","issuer_name":"Armata Pharmaceuticals, Inc.","issuer_ticker":"ARMP","issuer_name_source":null,"issuer_url":"/issuer/0000921114","owner_cik":null,"owner_name":"Innoviva, Inc.; Innoviva Strategic Opportunities LLC","owner_display_name":"Innoviva, Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4285935.0,"shares_display":"4,285,935","price_per_share":3.25,"price_display":"3.25","price_state":"stated","total_value":13929288.75,"total_display":"13,929,288.75","total_whole":"13,929,289","shares_owned_after":6153847.0,"shares_owned_after_display":"6,153,847","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-03-17","filed_date":"2021-03-17","scope":"insider"},{"id":4507673,"accession":"0000899243-21-003595","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-21-003595","line_url":"/filing/0000899243-21-003595#line-1","is_derivative":false,"issuer_cik":"0000921114","issuer_name":"Armata Pharmaceuticals, Inc.","issuer_ticker":"ARMP","issuer_name_source":null,"issuer_url":"/issuer/0000921114","owner_cik":null,"owner_name":"Innoviva, Inc.; Innoviva Strategic Opportunities LLC","owner_display_name":"Innoviva, Inc.","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":2,"other_reporting_owners":1,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1867912.0,"shares_display":"1,867,912","price_per_share":3.25,"price_display":"3.25","price_state":"stated","total_value":6070714.0,"total_display":"6,070,714.00","total_whole":"6,070,714","shares_owned_after":1867912.0,"shares_owned_after_display":"1,867,912","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-01-26","filed_date":"2021-01-28","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001724344","name":"Entasis Therapeutics Holdings Inc.","url":"/issuer/0001724344","role":"Director, Ten percent owner, Other","n_filings":3,"first_seen":"2021-05-20","last_seen":"2022-07-13"},{"type":"issuer","type_label":"ISSUER","cik":"0000921114","name":"Armata Pharmaceuticals, Inc.","url":"/issuer/0000921114","role":"Director, Ten percent owner","n_filings":5,"first_seen":"2021-01-28","last_seen":"2022-04-01"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001842875","retrieved_at":"2026-08-26T11:53:42+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-25","last_ingest":"2026-08-26T05:24:25.741053+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}